Absent, Enlarged, Confluent Saccules Best for Identifying Meniere Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, March 7, 2024 -- Absent, enlarged, or confluent saccules are the best predictors of Meniere disease (MD) on delayed postgadolinium magnetic resonance imaging (MRI), according to a study published online Feb. 7 in European Radiology.
Steve Connor, from King's College London, and colleagues conducted a retrospective single-center, case-control study examining delayed postgadolinium MRI of patients with menieriform symptoms. Seventeen MRI descriptors of MD were evaluated by two observers, and perilymphatic enhancement (PLE) in the cochlea was quantified. Definite MD ears were compared to control ears. The combination of MRI descriptors that would best predict MD ears was determined; and the area under the receiver operating characteristic curve (AUC) for this model was assessed.
A total of 227 patients with 96 definite MD ears and 78 control ears were examined. The researchers found the best performance for the presence of saccular abnormality (absent, as large as, or confluent with the utricle), with a diagnostic odds ratio of 292.6. Excellent reliability was demonstrated by all vestibular aqueduct descriptors, with diagnostic odds ratios of 7.761 to 18.1. Overall, 90.2 percent of cases were correctly classified by combining these saccular abnormalities with asymmetric cochlear PLE and an incompletely visualized vestibular aqueduct (sensitivity, 84.4 percent; specificity, 97.4 percent; AUC, 0.938).
"The radiologist should focus on these three highly performing descriptors in combination when reporting delayed postgadolinium MRI, to best corroborate the diagnosis of MD," the authors write.
One author is an employee of Siemens Healthcare.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.